New Combination Treatment for Aggressive Prostate Cancer
Developing A Novel Combinatorial Therapy for Lethal Neuroendocrine Prostate Cancer
This work explores new ways to combine treatments for neuroendocrine prostate cancer, a very aggressive form of prostate cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Duke University NIH-funded |
| Lab location | 1 site (Durham, United States) |
| Project ID | NIH-11141777 on NIH RePORTER |
What this research studies
Neuroendocrine prostate cancer (NEPC) is a serious type of prostate cancer that often develops after standard hormone treatments and has limited options. This project aims to find new targeted treatments by focusing on a common change in NEPC cells, called RB1 loss, which makes these cells vulnerable. Researchers are exploring a process called ferroptosis, a type of cell death, as a way to specifically target and eliminate these aggressive cancer cells. The goal is to develop a combination treatment that is more effective than current options for patients with NEPC.
Who could benefit from this research
Good fit: This research is most relevant to patients diagnosed with neuroendocrine prostate cancer, especially those whose cancer has progressed after hormone therapy.
Not a fit: Patients with early-stage prostate cancer or other types of cancer may not directly benefit from this specific research focus.
Why it matters
Potential benefit: If successful, this research could lead to new, more effective combination therapies for patients with aggressive neuroendocrine prostate cancer, where current treatments are often not enough.
How similar studies have performed: Previous research by this team suggests that targeting RB1 loss and inducing ferroptosis has therapeutic potential in NEPC, making this a promising, yet still early-stage, approach.
Where this research is happening
Durham, United States
- Duke University — Durham, United States (Active)
Researchers
- Principal investigator: Chen, Ming — Duke University
- Study coordinator: Chen, Ming
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.